Anteotech
- Short interest
- 0.00%
- −0.03 pp 30d
- as of 9 Oct 2026
- Reported shorts
- 1.3K
- Shares on issue
- 3.265B
Anteotech (ADO) Short Interest
Anteotech (ASX:ADO) had 0.00% of shares reported as short positions as of 9 Oct 2026, representing 1,321 shares. Anteotech operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4About Anteotech
Anteotech Ltd specializes in the development and commercialization of advanced medical diagnostics and energy storage solutions, leveraging its proprietary nanotechnology platform. It operates in healthcare and energy sectors, aiming for a significant market position through innovative solutions such as its proprietary AnteoBind™ technology, which enhances the sensitivity and performance of diagnostic assays.
Company profile →Anteotech (ASX:ADO) has 0.00% of its shares on issue reported as short positions as of 9 Oct 2026, or about 1,321 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.56% in February 2026. ADO is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Short interest
History & FAQ →Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.
Strategy fit
How each stock picker strategy reads ADO today
- Zanger BreakoutNot a candidate
- CAN SLIMWatchScore 15rank 837 of 1541
- Minervini Trend TemplateWatchScore 19rank 955 of 1716
- Crowded-Short BreakoutNot a candidate
- Quality compoundersNot a candidate
Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →
ADO fundamentals
In the year to 30 Jun 2026, Anteotech (ASX:ADO) recorded revenue of A$530.8K and a net loss after tax of A$5.4M. A year earlier it recorded revenue of A$968.9K and a net loss after tax of A$6.8M. Year-on-year growth: revenue −45.2% (FY). Net margin −1,012.8% (FY). Figures are in AUD, the company's reporting currency; source: ASX (Markit) and Yahoo Finance, as at 8 Oct 2026.
Full statements, ratios and filings are on the Financials tab. Not financial advice.
Latest ADO news
All news- AnteoTech Company Presentation - The Battery Show
asx · 13 Oct 2026
- Notice of Annual General Meeting/Proxy Form
asx · 6 Oct 2026
- Full Year Results and Business Update Presentation
asx · 29 Sept 2026
Company details
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss ADO
Start a research thread or post the first pulse update